RESEARCHER PROFILE

Panagiotis Petrou

← Back to University of Nicosia

P

University of Nicosia

Health Systems, Economic Evaluations, Quality of LifePharmaceutical Economics and PolicyHealthcare Systems and ReformsHealthcare Policy and ManagementEconomic and Financial Impacts of Cancer

Panagiotis Petrou works in Health Systems, Economic Evaluations, Quality of Life, Pharmaceutical Economics and Policy, Healthcare Systems and Reforms, Healthcare Policy and Management, Economic and Financial Impacts of Cancer. Recorded institutional associations include University Medical Center Groningen, University of Groningen, University of Nicosia.

77Publications
667Citations
15H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. A systematic review and meta-analysis of vitamin D and calcium in preventing osteoporotic fractures

    2020 · 48 citations
  2. Burden of non-communicable disease studies in Europe: a systematic review of data sources and methodological choices

    2021 · 37 citations
  3. Single-payer or a multipayer health system: a systematic literature review

    2018 · 35 citations
  4. Is it a Chimera? A systematic review of the economic evaluations of CAR-T cell therapy

    2019 · 31 citations
  5. Tendering for pharmaceuticals as a reimbursement tool in the Cyprus Public Health Sector

    2014 · 28 citations
  6. A systematic review of the economic evaluations of Enzyme Replacement Therapy in Lysosomal Storage Diseases

    2022 · 28 citations
  7. An Interrupted Time-Series Analysis to Assess Impact of Introduction of Co-Payment on Emergency Room Visits in Cyprus

    2015 · 26 citations
  8. The 2019 introduction of the new National Healthcare System in Cyprus

    2021 · 23 citations
  9. Cyprus in crisis: Recent changes in the pharmaceutical market and options for further reforms without sacrificing access to or quality of treatment

    2015 · 21 citations
  10. Failed Attempts to Reduce Inappropriate Laboratory Utilization in an Emergency Department Setting in Cyprus: Lessons Learned

    2015 · 19 citations
  11. Crisis as a serendipity for change in Cyprus' healthcare services

    2015 · 18 citations
  12. Cost–effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus

    2014 · 18 citations
  13. Methodological considerations in injury burden of disease studies across Europe: a systematic literature review

    2022 · 17 citations
  14. A Framework for Applying Health Technology Assessment in Cyprus: Thoughts, Success Stories, and Recommendations

    2013 · 16 citations
  15. A pilot study to assess feasibility of value based pricing in Cyprus through pharmacoeconomic modelling and assessment of its operational framework: sorafenib for second line renal cell cancer

    2014 · 15 citations
  16. A Comprehensive Molecular Epidemiological Analysis of SARS-CoV-2 Infection in Cyprus from April 2020 to January 2021: Evidence of a Highly Polyphyletic and Evolving Epidemic

    2021 · 15 citations
  17. Price Determinants of the Tendering Process for Pharmaceuticals in the Cyprus Market

    2015 · 14 citations
  18. Long-term effect of tendering on prices of branded pharmaceutical products

    2015 · 14 citations
  19. Co-payments for emergency department visits: a quasi-experimental study

    2019 · 14 citations
  20. Healthcare reforms in Cyprus 2013–2017: Does the crisis mark the end of the healthcare sector as we know it?

    2017 · 13 citations
  21. Comparison of validation protocols for blood pressure measuring devices in children and adolescents

    2022 · 13 citations
  22. Pharmacoeconomics in the years of crisis: a solution or just a resolution? A Cyprus perspective

    2014 · 12 citations
  23. Cost-effectiveness analysis of axitinib through a probabilistic decision model

    2015 · 11 citations
  24. The power of r – pharmaceutical sales decomposition in Cyprus public healthcare sector and determinants of drug expenditure evolution: any lessons learned?

    2014 · 11 citations
  25. Burden of disease attributable to risk factors in European countries: a scoping literature review

    2023 · 11 citations

← Return to the university profile